Literature DB >> 21598016

[Vaccination prior to travelling for patients with rheumatic diseases].

B Ehrenstein1.   

Abstract

Rheumatologists increasingly face patient questions about the need, the safety and the effectiveness of travel-related vaccinations. Currently, there are no guidelines on travel vaccinations for patients with inflammatory rheumatic diseases. The use of live attenuated vaccines remains contraindicated in patients receiving relevant immunosuppressive therapy despite some encouraging results from initial pilot studies. However, many inactivated travel vaccines can safely be used for patients with rheumatic diseases. Furthermore, rheumatologists should be vigilant in identifying and closing gaps in the routine vaccinations for patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21598016     DOI: 10.1007/s00393-010-0721-2

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  15 in total

1.  Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study.

Authors:  Camilla Bengtsson; Meliha C Kapetanovic; Henrik Källberg; Berit Sverdrup; Birgitta Nordmark; Lars Klareskog; Lars Alfredsson
Journal:  Ann Rheum Dis       Date:  2010-07-05       Impact factor: 19.103

2.  Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.

Authors:  M C Kapetanovic; T Saxne; A Sjöholm; L Truedsson; G Jönsson; P Geborek
Journal:  Rheumatology (Oxford)       Date:  2005-11-15       Impact factor: 7.580

3.  Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients.

Authors:  K Stark; M Günther; R Neuhaus; P Reinke; K Schröder; S Linnig; U Bienzle
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

4.  Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids.

Authors:  Gecilmara Salviato Pileggi; Cleonice Barbosa Sandoval de Souza; Virgínia Paes Leme Ferriani
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07       Impact factor: 4.794

5.  Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.

Authors:  Jeffrey L Kaine; Alan J Kivitz; Charles Birbara; Allison Y Luo
Journal:  J Rheumatol       Date:  2007-02       Impact factor: 4.666

6.  [Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases].

Authors:  Licia Maria Henrique da Mota; Ana Cristina Vanderley Oliveira; Rodrigo Aires Corrêa Lima; Leopoldo Luiz dos Santos-Neto; Pedro Luiz Tauil
Journal:  Rev Soc Bras Med Trop       Date:  2009 Jan-Feb       Impact factor: 1.581

7.  Overwhelming parasitemia with Plasmodium falciparum infection in a patient receiving infliximab therapy for rheumatoid arthritis.

Authors:  Estella M Geraghty; Bryan Ristow; Shelley M Gordon; Paul Aronowitz
Journal:  Clin Infect Dis       Date:  2007-04-02       Impact factor: 9.079

8.  Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.

Authors:  Clifton O Bingham; R John Looney; Atul Deodhar; Neal Halsey; Maria Greenwald; Christine Codding; Benjamin Trzaskoma; Flavius Martin; Sunil Agarwal; Ariella Kelman
Journal:  Arthritis Rheum       Date:  2010-01

Review 9.  Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs.

Authors:  Angela Marie Danerseau; Joan Louise Robinson
Journal:  World J Pediatr       Date:  2008-12-23       Impact factor: 9.186

10.  Effectiveness and economic analysis of the whole cell/recombinant B subunit (WC/rbs) inactivated oral cholera vaccine in the prevention of traveller's diarrhoea.

Authors:  Rosa López-Gigosos; Pedro Garcia-Fortea; Maria J Calvo; Emilia Reina; Rosa Diez-Diaz; Elena Plaza
Journal:  BMC Infect Dis       Date:  2009-05-16       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.